View Older Stories

Oct 14, 2025 07:33AM Merus reports early data on petosemtamab for colorectal cancer

Oct 13, 2025 12:00PM Merus petosemtamab data selected for plenary session at cancer conference

Oct 6, 2025 02:44AM Leerink Partners Downgrades Merus N.V. (MRUS) to Market Perform

Oct 4, 2025 04:00PM Why UBS says Q4 is eventful for SMID oncology stocks

Sep 30, 2025 04:04AM BMO Capital Downgrades Merus N.V. (MRUS) to Market Perform

Sep 30, 2025 03:27AM Barclays Downgrades Merus N.V. (MRUS) to Equalweight

Sep 30, 2025 02:50AM Guggenheim Downgrades Merus N.V. (MRUS) to Neutral

Sep 30, 2025 02:03AM UBS Downgrades Merus N.V. (MRUS) to Neutral

Sep 29, 2025 01:09PM Genmab A/S (GMAB) PT Raised to $34 at Leerink Partners

Sep 29, 2025 11:55AM Canaccord Genuity Downgrades Merus N.V. (MRUS) to Hold

Sep 29, 2025 10:57AM William Blair Downgrades Merus N.V. (MRUS) to Market Perform

Sep 29, 2025 10:09AM Truist Securities Downgrades Merus N.V. (MRUS) to Hold

Sep 29, 2025 08:48AM Wells Fargo Downgrades Merus N.V. (MRUS) to Equal Weight

Sep 29, 2025 08:24AM Needham Downgrades Merus N.V. (MRUS) to Hold

Sep 29, 2025 07:48AM Citi Downgrades Merus N.V. (MRUS) to Neutral

Sep 17, 2025 04:35AM Barclays Starts Merus N.V. (MRUS) at Overweight

Sep 8, 2025 09:45AM BofA Securities on Merus N.V. (MRUS): 'one of our top picks for the remainder of 2025'

Aug 25, 2025 07:32AM Alliance Global Partners Starts Merus N.V. (MRUS) at Buy

Jun 4, 2025 06:15AM Merus N.V. (MRUS) Prices 5.26M Share Offering at $57/sh

Jun 3, 2025 04:07PM Merus N.V. (MRUS) Announces Proposed Share Offering

May 28, 2025 04:25AM Citizens JMP shares updates on cancer treatment stocks

May 27, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on Merus N.V. (MRUS)

May 23, 2025 10:36AM 'Merus N.V. (MRUS) Changing the Game in HNSCC'; PT Raised to $110 at BMO Capital

May 23, 2025 10:24AM Truist: 'Merus N.V. (MRUS) Delivers A True Home Run'

May 23, 2025 07:23AM Merus N.V. (MRUS) PT Raised to $88 at Needham

May 22, 2025 05:37PM Merus N.V. (MRUS) announces interim clinical data for Phase 2 trial of petosemtamab

May 16, 2025 10:00AM Truist 'Increasingly Optimistic' About Merus N.V. (MRUS) Data

May 15, 2025 08:02AM Merus N.V. (MRUS) Announces the Journal Publication of Petosemtamab Mechanism of Action

May 7, 2025 06:10PM Merus N.V. (MRUS) Misses Q1 EPS by 29c

Mar 6, 2025 09:45AM Stifel Reiterates Buy Rating on Merus N.V. (MRUS)

Mar 3, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on Merus N.V. (MRUS)

Feb 28, 2025 08:59AM Merus N.V. (MRUS) PT Raised to $96 at BMO Capital; 'Peto Remains Our 2025 Value-Driver'

Feb 18, 2025 08:01AM Merus N.V. (MRUS): Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Feb 13, 2025 03:22AM Piper Sandler Starts Merus N.V. (MRUS) at Overweight

Feb 7, 2025 07:22AM Wells Fargo Starts Merus N.V. (MRUS) at Overweight

Jan 13, 2025 03:06PM Merus N.V. (MRUS) at the money February 40 calls active as share price down 7.5%

Dec 9, 2024 01:03PM Merus N.V. (MRUS) PT Raised to $97 at Citi

Dec 4, 2024 04:55PM Merus N.V. (MRUS) Announces FDA Approval of BIZENGRI

Dec 4, 2024 03:49PM Merus N.V. (MRUS) Receives FDA Accelerated Approval for Zenocutuzumab-zbco

Dec 3, 2024 06:50AM Merus N.V. (MRUS) PT Lowered to $109 at Guggenheim

Dec 2, 2024 01:03PM BMO Capital Maintains Outperform Rating on Merus N.V. (MRUS), Reiterates Top Pick Designation

Dec 2, 2024 08:02AM Merus (MRUS) and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Dec 2, 2024 06:43AM H.C. Wainwright Reiterates Buy Rating on Merus N.V. (MRUS)

Nov 21, 2024 03:39AM Goldman Sachs Starts Merus N.V. (MRUS) at Buy

Nov 5, 2024 06:33AM Merus N.V. (MRUS) Receives FDA extension of PDUFA for zenocutuzumab

Nov 5, 2024 06:33AM Merus N.V. (MRUS) Receives FDA extension of PDUFA for zenocutuzumab

Oct 24, 2024 04:02AM UBS Starts Merus N.V. (MRUS) at Buy

Sep 30, 2024 03:41PM BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

Sep 30, 2024 08:04AM Merus (MRUS) Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC

Aug 5, 2024 07:08AM Merus N.V. (MRUS) PT Lowered to $85 at Needham

View Older Stories